GSK
4 years ago ⋅ English ⋅ 4 min read
Newsroom
FDA grants Priority Review to ViiV Healthcare’s New Drug Application for cabotegravir long-acting for prevention of HIV

For media and investors onlyFinal FDA decision anticipated by 23 January 2022; if approved, cabotegravir would be the first long-acting therapy for HIV PrEPLondon, 28 September 2021 &nd... Read More
GSK
4 years ago ⋅ English ⋅ 7 min read
Newsroom
ViiV Healthcare announces exclusive license agreement with Shionogi to develop third-generation HIV integrase inhibitor with potential for ultra long-acting dosing intervals

For media and investors only- S-365598 aims to build on the success of dolutegravir and cabotegravir with potential to anchor the next generation of VHC’s future pipeline of innov... Read More
GSK
4 years ago ⋅ English ⋅ 3 min read
Newsroom
Changing attitudes to vaccination after the COVID-19 pandemic could increase adult vaccination rates, improving health outcomes over the longer term

For media and investors onlyIssued: 22 September 2021, London UK- GSK-sponsored Kantar survey shows that people 50 years of age and older value good health and improved quality of life... Read More
GSK
4 years ago ⋅ English ⋅ 14 min read
Newsroom
ViiV Healthcare to present key data that provides further support for the use of 2-drug regimens, including long-term efficacy, alongside new insights into living with HIV at IDWeek 2021

For media and investors onlyViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced the presenta... Read More
GSK
4 years ago ⋅ English ⋅ 4 min read
Newsroom
GSK announces major renewable energy investment and low carbon inhaler programme alongside Life Sciences sector Race to Zero ‘breakthrough’ at NYC Climate Week

For media and investors only- Company announces £50m investment in renewable energy and carbon reduction at major UK and US manufacturing sites as CEO Emma Walmsley takes part in... Read More
GSK
4 years ago ⋅ English ⋅ 6 min read
Newsroom
GSK receives CHMP positive opinions recommending approval of Nucala (mepolizumab) in three additional eosinophil-driven diseases

For media and investors onlyIssued: 17 September 2021, London UK- If approved in Europe, mepolizumab would be the only treatment indicated for use in four eosinophil-driven diseases- CH... Read More